$CTMX
CytomX Therapeutics Inc

2019 Q4 Form 10-Q Financial Statement

#000156459019041726 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q3
Revenue $8.279M $10.71M $12.51M
YoY Change -27.83% -14.37% -48.19%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.220M $8.460M $8.140M
YoY Change 2.67% 3.93% 30.24%
% of Gross Profit
Research & Development $36.44M $27.97M $27.55M
YoY Change 28.72% 1.52% -4.74%
% of Gross Profit
Depreciation & Amortization $600.0K $700.0K $500.0K
YoY Change 0.0% 40.0% 35.87%
% of Gross Profit
Operating Expenses $45.66M $36.43M $35.69M
YoY Change 22.48% 2.08% 1.47%
Operating Profit -$25.72M -$23.18M
YoY Change 10.96% 110.22%
Interest Expense $1.510M $2.000M $2.220M
YoY Change -39.84% -9.91% 174.07%
% of Operating Profit
Other Income/Expense, Net -$10.00K $22.00K $29.00K
YoY Change -50.0% -24.14% -161.7%
Pretax Income -$35.88M -$23.70M -$20.93M
YoY Change 53.85% 13.24% 103.87%
Income Tax -$420.0K $0.00 $2.500M
% Of Pretax Income
Net Earnings -$35.46M -$23.70M -$23.43M
YoY Change 10.0% 1.14% 128.66%
Net Earnings / Revenue -428.25% -221.24% -187.31%
Basic Earnings Per Share
Diluted Earnings Per Share -$780.0K -$521.8K -$533.5K
COMMON SHARES
Basic Shares Outstanding 45.43M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $296.1M $325.7M $464.6M
YoY Change -32.1% -29.89% 40.24%
Cash & Equivalents $188.4M $164.6M $259.8M
Short-Term Investments $107.7M $161.1M $204.8M
Other Short-Term Assets $7.200M $9.100M $7.900M
YoY Change -22.58% 15.19% 64.58%
Inventory
Prepaid Expenses
Receivables $13.00K $7.000K $56.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $303.3M $334.8M $472.5M
YoY Change -31.91% -29.15% 25.53%
LONG-TERM ASSETS
Property, Plant & Equipment $7.372M $7.107M $5.482M
YoY Change 6.32% 29.64% 33.71%
Goodwill $949.0K $949.0K $949.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.015M $1.375M $1.375M
YoY Change 46.55% 0.0% -65.63%
Total Long-Term Assets $37.95M $37.77M $10.22M
YoY Change 226.2% 269.6% -3.6%
TOTAL ASSETS
Total Short-Term Assets $303.3M $334.8M $472.5M
Total Long-Term Assets $37.95M $37.77M $10.22M
Total Assets $341.3M $372.5M $482.7M
YoY Change -25.34% -22.82% 24.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.158M $4.550M $6.871M
YoY Change -18.98% -33.78% 136.93%
Accrued Expenses $30.05M $20.50M $21.42M
YoY Change 12.45% -4.3% 87.86%
Deferred Revenue $51.38M $51.08M $53.00M
YoY Change -2.53% -3.62%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $85.59M $76.13M $86.27M
YoY Change -12.58% -11.76% 21.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $850.0K $963.0K $2.426M
YoY Change -72.13% -60.31% -99.1%
Total Long-Term Liabilities $850.0K $963.0K $2.426M
YoY Change -72.13% -60.31% -99.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $85.59M $76.13M $86.27M
Total Long-Term Liabilities $850.0K $963.0K $2.426M
Total Liabilities $290.2M $290.4M $325.1M
YoY Change -11.05% -10.65% -4.84%
SHAREHOLDERS EQUITY
Retained Earnings -$417.2M -$381.8M -$282.7M
YoY Change 32.46% 35.02%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $51.11M $82.11M $157.7M
YoY Change
Total Liabilities & Shareholders Equity $341.3M $372.5M $482.7M
YoY Change -25.34% -22.82% 24.74%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q3
OPERATING ACTIVITIES
Net Income -$35.46M -$23.70M -$23.43M
YoY Change 10.0% 1.14% 128.66%
Depreciation, Depletion And Amortization $600.0K $700.0K $500.0K
YoY Change 0.0% 40.0% 35.87%
Cash From Operating Activities -$29.50M -$23.30M -$5.600M
YoY Change 2.79% 316.07% -1.75%
INVESTING ACTIVITIES
Capital Expenditures -$700.0K -$600.0K -$1.100M
YoY Change -36.36% -45.45%
Acquisitions
YoY Change
Other Investing Activities $53.60M $39.10M -$2.100M
YoY Change 217.16% -1961.9% -113.13%
Cash From Investing Activities $52.90M $38.50M -$3.200M
YoY Change 234.81% -1303.13% -120.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 400.0K 0.000 135.6M
YoY Change -42.86% -100.0% 12227.27%
NET CHANGE
Cash From Operating Activities -29.50M -23.30M -5.600M
Cash From Investing Activities 52.90M 38.50M -3.200M
Cash From Financing Activities 400.0K 0.000 135.6M
Net Change In Cash 23.80M 15.20M 126.8M
YoY Change -295.08% -88.01% 1012.28%
FREE CASH FLOW
Cash From Operating Activities -$29.50M -$23.30M -$5.600M
Capital Expenditures -$700.0K -$600.0K -$1.100M
Free Cash Flow -$28.80M -$22.70M -$4.500M
YoY Change 4.35% 404.44% -21.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9058000
CY2019Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
161067000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
334778000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7107000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Local Phone Number
LocalPhoneNumber
515-3185 
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
247577000
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei Entity File Number
EntityFileNumber
001-37587
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3521219
dei Entity Address Address Line1
EntityAddressAddressLine1
151 Oyster Point Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
188550000
dei City Area Code
CityAreaCode
650
CY2019Q3 us-gaap Goodwill
Goodwill
949000
CY2019Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1349000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9251000
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
445475000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6934000
CY2018Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1458000
CY2018Q4 us-gaap Goodwill
Goodwill
949000
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2019Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2019Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1375000
CY2019Q3 us-gaap Assets
Assets
372544000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4550000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20496000
CY2018Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
13339000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
963000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3050000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27967000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1997000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23699000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2502000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
465000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5192000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
155000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-14124000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
122571000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
665000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1602000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5454000
CY2019Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
136000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-28960000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4343000
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-99000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-23699000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
82109000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
69896000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2602000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3688000
CY2018Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-134000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15493000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
49647000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
366000
CY2018Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
356000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4161000
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
50000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-13447000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
41133000
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
134596000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
981000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4412000
CY2018Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-30000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45434164
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164646000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49210000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43917510
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8137000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
36430000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
35686000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95178000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8463000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25718000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27549000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75560000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12509000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48031000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
457108000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
97000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
445956000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45083209
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45083209
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-93000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314981000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
130883000
CY2018Q4 us-gaap Liabilities
Liabilities
326225000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2019Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
187725000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26069000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
225267000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1375000
CY2018Q4 us-gaap Assets
Assets
457108000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5132000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26724000
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
51080000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
52713000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
76126000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
97908000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25621000
CY2019Q3 us-gaap Liabilities
Liabilities
290435000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45426468
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45426468
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
463773000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
110000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-381775000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
82109000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
372544000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10712000
us-gaap Operating Expenses
OperatingExpenses
122726000
us-gaap Operating Expenses
OperatingExpenses
100095000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23177000
us-gaap Operating Income Loss
OperatingIncomeLoss
-73516000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52064000
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2219000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6854000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5134000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.47
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-50000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20929000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66788000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46980000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5391000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-23699000
us-gaap Net Income Loss
NetIncomeLoss
-66782000
us-gaap Net Income Loss
NetIncomeLoss
-52371000
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.52
CY2018Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.53
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45294593
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23461000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40528105
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.29
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-114000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45418053
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
192000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24535000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
130883000
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-99000
CY2018Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-30000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23798000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66579000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27548000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-126000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-23431000
us-gaap Tax Cuts And Jobs Act Of2017 Reclassification From Aoci To Retained Earnings Tax Effect
TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
11000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
101501000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
247577000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
259753000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
177548000
CY2019Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2018Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
165563000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
248494000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
260670000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
178465000
ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
10000000.0
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
238805000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52485000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-90000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-193000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3538000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
20000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-23431000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
157661000
us-gaap Profit Loss
ProfitLoss
-66782000
us-gaap Profit Loss
ProfitLoss
-52371000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
109000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
109000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1888000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1276000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1963000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1114000
us-gaap Share Based Compensation
ShareBasedCompensation
14989000
us-gaap Share Based Compensation
ShareBasedCompensation
12262000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1602000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10083000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
152000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2795000
ctmx Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
-22104000
ctmx Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
10552000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-39175000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-26813000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111001000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46779000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2794000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2669000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
149532000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
161743000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
179170000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
154496000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26844000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9916000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
134596000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1226000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4304000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1226000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
138900000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-82931000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
82205000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
248494000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
178465000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
165563000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
260670000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
293000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
233000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:10pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the Business</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapeutics. The Company is pioneering a novel class of investigational antibody therapeutics, based on its Probody™ therapeutic technology platform, for the treatment of cancer. The Probody therapeutic approach is designed to more specifically target antibody therapeutics to the tumor microenvironment and minimize drug activity in healthy tissue and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p>
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164646000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2019Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
307778000
CY2019Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
167000
CY2019Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
307945000
CY2019Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
0
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
416512000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
66000
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
416446000
CY2019Q3 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
11319000
CY2018Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
18520000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5159000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6585000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
981000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
830000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2719000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
318000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
789000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20496000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26724000
CY2019Q3 us-gaap Revenues
Revenues
10712000
CY2018Q3 us-gaap Revenues
Revenues
12509000
us-gaap Revenues
Revenues
49210000
us-gaap Revenues
Revenues
48031000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
277980000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
10000000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
49175000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
49200000
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
238800000
CY2019Q3 ctmx Royalty Obligations Future Minimum Payments Due
RoyaltyObligationsFutureMinimumPaymentsDue
150000
ctmx License Termination Period
LicenseTerminationPeriod
P60D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7803773
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.62
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2624983
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.77
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
112197
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
632038
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
17.63
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9684521
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.70
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5801190
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.00
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4343000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4413000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14989000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12262000
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
CY2018Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3800000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3800000
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1205000
us-gaap Operating Lease Payments
OperatingLeasePayments
3615000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26069000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2719000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25621000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
28340000
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1239000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4990000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5129000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5273000
CY2019Q3 ctmx Lessee Operating Lease Liability Payments Due Year Five And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
21109000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
37740000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9400000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
28340000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2500000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5400000
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.120
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.115

Files In Submission

Name View Source Status
0001564590-19-041726-index-headers.html Edgar Link pending
0001564590-19-041726-index.html Edgar Link pending
0001564590-19-041726.txt Edgar Link pending
0001564590-19-041726-xbrl.zip Edgar Link pending
ctmx-10q_20190930.htm Edgar Link pending
ctmx-10q_20190930_htm.xml Edgar Link completed
ctmx-20190930.xsd Edgar Link pending
ctmx-20190930_cal.xml Edgar Link unprocessable
ctmx-20190930_def.xml Edgar Link unprocessable
ctmx-20190930_lab.xml Edgar Link unprocessable
ctmx-20190930_pre.xml Edgar Link unprocessable
ctmx-ex101_559.htm Edgar Link pending
ctmx-ex102_564.htm Edgar Link pending
ctmx-ex103_563.htm Edgar Link pending
ctmx-ex104_562.htm Edgar Link pending
ctmx-ex105_561.htm Edgar Link pending
ctmx-ex106_560.htm Edgar Link pending
ctmx-ex311_8.htm Edgar Link pending
ctmx-ex312_7.htm Edgar Link pending
ctmx-ex321_10.htm Edgar Link pending
ctmx-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g5qijpkapw2f000001.jpg Edgar Link pending
gfgjrdt5f1n0000001.jpg Edgar Link pending
gfgjrdt5f1n0000002.jpg Edgar Link pending
gxultspa5oia000001.jpg Edgar Link pending
gzqnrktxoexo000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending